0.0215EUR+5.39%Mkt Cap: 1.91M EURP/E: —Last update: 2026-05-14
Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients with age-related diseases. The company'…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Valuation
P/E (Trailing)—
P/E (Forward)-0.01
PEG—
P/B-0.06
P/S—
EV/EBITDA-0.89
EV/Revenue—
EPS (TTM)-0.34
EPS (Forward)-2.15
Cash Flow & Leverage
FCF Yield-85.85%
FCF Margin—
Operating CF-8.64M EUR
CapEx (TTM)—
Net Debt/EBITDA-0.83
Net Debt6.51M EUR
Technical
SMA 500.0235 (-8.5%)
SMA 2000.0864 (-75.1%)
Beta0.86
S&P 52W Chg24.23%
Avg Vol (30d)6.08M
Avg Vol (10d)7.22M
Technical Indicators
RSI (14)48.8
MACD-0.0009
MACD Signal-0.0015
MACD Hist.+0.0006
BB Upper0.0268 EUR
BB Middle0.0204 EUR
BB Lower0.0141 EUR
BB Width61.84%
ATR (14)0.0039 EUR
Vol Ratio (20d)1.13x
52W Range
0.01533% of range0.2180
52W High0.2180 EUR
52W Low0.0153 EUR
Profitability
Gross Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
Oper. Margin0.00%
ROE—
ROA-66.56%
Revenue Growth—
Earnings Growth—
Balance Sheet
Debt/Equity-0.68
Current Ratio0.35
Quick Ratio0.33
Book Value/Sh-0.3330 EUR
Cash/Share0.0520 EUR
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 EUR
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:400
Split DateMay 3, 2024
Ownership
Shares Out.91.63M
Float23.36M
Insiders0.32%
Institutions1.61%
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Company
Market Cap1.91M EUR
Enterprise Value6.96M EUR
Revenue (TTM)—
Gross Profit0 EUR
Net Income (TTM)-8.03M EUR
Revenue/Share—
Fiscal Year EndDec 2024
MR QuarterJun 2025
Employees19
Last Price0.0215 EUR
CountryFR
SectorHealthcare
IndustryBiotechnology
ISIN—